---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-26-000516"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T02:44:40.206813+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunic appoints Michael Panzara as CMO; prior CMO Andreas Muehler resigns, transitions to consultant

## Summary
- Michael Panzara appointed CMO effective April 24, 2026; base salary $600K, annual bonus target ≥50% of salary, signing bonus $125K.
- Andreas Muehler resigned as CMO effective April 27, 2026; will serve as Senior Medical Officer through April 30, then consultant 10 months at $10K/month.
- Panzara granted inducement option for 300K shares (post-split) vesting 50% at 1 year, 50% over 24 months thereafter.
- Muehler receives 12 months base salary severance, pro-rated FY2026 bonus, full equity vesting, and 3-year post-termination exercise window.
- No disagreement cited for Muehler's departure; Panzara brings >25 years neurology drug development experience including MS approvals at Biogen/Sanofi.

## SEC filing metadata
- accession: 0001193805-26-000516
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000516/0001193805-26-000516-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000516/e665394_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-26-000516
- JSON: https://secwatch.observer/filing/0001193805-26-000516.json
- Plain text: https://secwatch.observer/filing/0001193805-26-000516.txt

## Key facts
- Executive change
  Michael A. Panzara was appointed as Chief Medical Officer at IMMUNIC, INC..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: Immunic, Inc. (the "Company") appointed Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000516/0001193805-26-000516-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.